E2F1 Antibody - #AF6377

(6)   (5)  
Product: E2F1 Antibody
Catalog: AF6377
Description: Rabbit polyclonal antibody to E2F1
Application: WB IF/ICC
Reactivity: Human, Mouse
Prediction: Pig, Bovine, Horse, Rabbit, Chicken
Mol.Wt.: 47,70kDa; 47kD(Calculated).
Uniprot: Q01094
RRID: AB_2835219

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Chicken(82%)
Clonality:
Polyclonal
Specificity:
E2F1 Antibody detects endogenous levels of total E2F1.
RRID:
AB_2835219
Cite Format: Affinity Biosciences Cat# AF6377, RRID:AB_2835219.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Dmel\CG6376; Dmel_CG6376; drosE2F1; E(Sev-CycE)3A; E(var)3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2f-PA; E2f-PB; E2f-PC; E2F1; E2f1 E2F transcription factor 1; E2F1_HUMAN; Evar(3)164; KIAA4009; l(3)07172; l(3)j3B1; l(3)j3C2; l(3)rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1;

Immunogens

Immunogen:
Uniprot:

Q01094(E2F1_HUMAN) >>Visit HPA database.

Gene(ID):
E2F1(1869)
Description:
The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses.
Sequence:
MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPARGRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQQLDHLMNICTTQLRLLSEDTDSQRLAYVTCQDLRSIADPAEQMVMVIKAPPETQLQAVDSSENFQISLKSKQGPIDVFLCPEETVGGISPGKTPSQEVTSEEENRATDSATIVSPPPSSPPSSLTTDPSQSLLSLEQEPLLSRMGSLRAPVDEDRLSPLVAADSLLEHVREDFSGLLPEEFISLSPPHEALDYHFGLEEGEGIRDLFDCDFGDLTPLDF

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Rabbit
100
Chicken
82
Zebrafish
73
Sheep
0
Dog
0
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q01094 As Substrate

Site PTM Type Enzyme
Phosphorylation
S31 Phosphorylation Q13315 (ATM) , Q13535 (ATR)
T96 Phosphorylation
R109 Methylation
R111 Methylation
R113 Methylation
K117 Acetylation
K120 Acetylation
S121 Phosphorylation
K125 Acetylation
T135 Phosphorylation
T136 Phosphorylation
K161 Ubiquitination
K164 Ubiquitination
K185 Methylation
S307 Phosphorylation
S332 Phosphorylation Q9UHD2 (TBK1) , P06493 (CDK1)
S337 Phosphorylation P06493 (CDK1) , O43318 (MAP3K7)
S364 Phosphorylation O96017 (CHEK2) , P49137 (MAPKAPK2) , Q683Z8 (CHK2)
S375 Phosphorylation P49336 (CDK8)
S403 Phosphorylation P32780 (GTF2H1) , P49841 (GSK3B) , Q15759 (MAPK11) , O15111 (CHUK) , P50613 (CDK7)
T433 Phosphorylation P49841 (GSK3B) , P32780 (GTF2H1) , P50613 (CDK7) , Q15759 (MAPK11)

Research Backgrounds

Function:

Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B.

PTMs:

Phosphorylated by CDK2 and cyclin A-CDK2 in the S-phase. Phosphorylation at Ser-364 by CHEK2 stabilizes E2F1 upon DNA damage and regulates its effect on transcription and apoptosis.

Acetylation stimulates DNA-binding. Enhanced under stress conditions such as DNA damage and inhibited by retinoblastoma protein RB1. Regulated by KAP1/TRIM28 which recruits HDAC1 to E2F1 resulting in deacetylation. Acetylated by P/CAF/KAT2B.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Component of the DRTF1/E2F transcription factor complex. Forms heterodimers with DP family members. The E2F1 complex binds specifically hypophosphorylated retinoblastoma protein RB1. During the cell cycle, RB1 becomes phosphorylated in mid-to-late G1 phase, detaches from the DRTF1/E2F complex, rendering E2F transcriptionally active. Viral oncoproteins, notably E1A, T-antigen and HPV E7, are capable of sequestering RB1, thus releasing the active complex. Interacts with TRRAP, which probably mediates its interaction with histone acetyltransferase complexes, leading to transcription activation. Binds TOPBP1 and EAPP. Interacts with ARID3A. Interacts with TRIM28; the interaction inhibits E2F1 acetylation through recruiting HDAC1 and represses its transcriptional activity. Interaction with KAT2B; the interaction acetylates E2F1 enhancing its DNA-binding and transcriptional activity. Interacts with BIRC2/c-IAP1 (via BIR domains). The complex TFDP1:E2F1 interacts with CEBPA; the interaction prevents CEBPA binding to target genes promoters and represses its transcriptional activity. Interacts with RRP1B. Interacts with HCFC1. Interacts with KMT2E; the interaction is probably indirect and is mediated via HCFC1.

(Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL123.

Family&Domains:

Belongs to the E2F/DP family.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

References

1). Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). Journal of Experimental & Clinical Cancer Research, 2017 (PubMed: 28797284) [IF=11.3]

Application: WB    Species: human    Sample:

Fig. 7 Gambogic acid (GA) reduces the expression of ribonucleotide reductase subunit-M2 (RRM2) by inhibiting the ERK/E2F1 signaling pathway. a PANC-1 and BxPC-3 cells were treated with 1, 2, and 4 μM GA for 24 h, respectively. Protein levels of RRM2 and E2F1 were detected using western blot analysis. b, c PANC-1 and BxPC-3 cells were treated with si-E2F1 for 48 h, and protein levels of RRM2 and E2F1 were detected using western blot analysis (b); the mRNA levels of RRM2 and E2F1 were detected by q-PCR (C). (D, E) PANC-1 and BxPC-3 cells were treated with 1 μM GA or 5 μM gemcitabine alone, or in combination (GA with gemcitabine) for 24 h. Expression of the p-ERK, ERK, E2F1 and RRM2 proteins were detected using western blot analysis and q-PCR (d).
2). Discovery of N-(4-(3-isopropyl-2-methyl-2 H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies. Journal of medicinal chemistry, 2021 (PubMed: 34415148) [IF=7.3]
3). Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway. Biochemical pharmacology, 2023 (PubMed: 37863326) [IF=5.8]

Application: WB    Species: Human    Sample: A375 and SK-MEL-28 cell

Fig. 6. E2F1 was identified as one target of H2A.Z.1. (A) Analysis of the downstream transcription factors of the co-expressed genes significantly associated with H2AFZ (encoding H2A.Z.1) based on LinkedOmics database. (B) Expression correlation of H2AFZ and E2F1 by GSEA transcriptional regulation analysis. (C) Correlation analysis between mRNA expression of H2A.Z.1 and E2F1. (D) With or without ISL administration for 48 h, the expression of E2F1 in two cell lines (A375 and SK-MEL-28) transfected with empty vector or H2A.Z.1-overexpressed plasmid were detected by western blot. (E) The expression level of E2F1 in SKCM and normal tissues based on TCGA database. (F) The overall survival and progression-free survival (PFS) time in patients with high and low expression of E2F1. The data represented the mean ± SEM of three independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant.
4). Indoxyl sulfate promotes the atherosclerosis through up-regulating the miR-34a expression in endothelial cells and vascular smooth muscle cells in vitro. VASCULAR PHARMACOLOGY, 2020 (PubMed: 32593718) [IF=4.0]

Application: WB    Species: human    Sample: HUVECs and HA-VSMCs

Fig. 7.| IS inhibits the Notch signaling pathway and miR-34a-related protein. After transfection with miR-34a mimics (50 nM) or inhibitor (100 nM), IS (1000 μM) was added and incubated for another 36 h. Western blotting was used to detected the protein expression in HUVECs and HA-VSMCs. Data are represented as the mean ± SEM (n = 3). ⁎P < .05, versus control, #P < .05, versus IS group by one-way ANOVA with Tukey's test
5). Columbianetin acetate inhibits the occurrence and development of pancreatic cancer cells by down-regulating the expression of Meiotic nuclear divisions 1.. Biocell, 2019 [IF=1.2]
6). Expression Profiles of HOXC6 Predict the Survival of Glioblastoma Patients and Correlate with Cell Cycle. Journal of Oncology, 2022 (PubMed: 35432534)

Application: WB    Species: Human    Sample: LN229 cells

Figure 5 Tumor cell biology experiments of HOXC6. (a) Expression of HOXC6 after transfection of siRNA or overexpression plasmid measured by PCR. (b) CCK-8 assay to evaluate the effect of HOXC6 knockdown or overexpression on cell proliferation in LN229 cells. ∗p < 0.05, ∗∗p < 0.01. (c) CCK-8 assay to evaluate the effect of HOXC6 knockdown or overexpression on cell proliferation in T98G cells. From left to right: NC, OE, and SI. (d) Flow cytometry analysis to evaluate the effects of HOXC6 on cell cycle progression in LN229 cells. (e) Flow cytometry analysis to evaluate the effects of HOXC6 on cell cycle progression in T98G cells. From left to right: NC, OE, and SI. (f) Western blot analysis to evaluate the effects of HOXC6 on expression level of cell cycle related proteins.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.